We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.52 | 1.48% | 104.0001 | 6,863,431 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 103.6761 | 102.66 | 102.91 | |||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.28B | 14.52B | 5.7296 | 18.06 | 262.17B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 00:58:27 | formt | 100 | 104.0001 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/11/2023 | 19:10 | DJN | Merck Raises Quarterly Dividend 5.5% To 77 Cents |
| 10/11/2023 | 13:35 | DJN | Merck Gets CHMP Backing for Keytruda in Biliary Tract Cancer |
| 30/10/2023 | 12:45 | IHNW | Can Diabetes, Weight-Loss Drugs Get Even Better? |
| 26/10/2023 | 12:05 | DJN | Merck 3Q Profit Rose as Sales of Breast Cancer Treatment Jumped |
| 20/10/2023 | 18:37 | DJN | Trending: Merck, Daiichi Sankyo Sign Development, Commercialization Deal |
| 20/10/2023 | 00:30 | DJN | Merck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 Billion |
| 16/10/2023 | 23:55 | DJN | Merck Gets FDA Approval for Resectable Lung Cancer Treatment With Keytruda.. |
| 10/10/2023 | 11:17 | DJN | Merck: Phase 3 Keytruda Study Hits Second Goal in Non-Small Cell Lung.. |
| 05/10/2023 | 11:47 | DJN | Merck Keytruda Study Hits Key Goal in Advanced Bladder Cancer |
| 28/9/2023 | 11:41 | DJN | Merck Gets FDA Priority Review of Sotatercept in Pulmonary Arterial.. |
Merck (MRK) Share Charts1 Year Merck Chart |
|
1 Month Merck Chart |
Intraday Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
